Filtered By:
Management: National Institutes of Health (NIH)
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 16 results found since Jan 2013.
COVID-19 SeroHub, an online repository of SARS-CoV-2 seroprevalence studies in the United States
Sci Data. 2022 Nov 26;9(1):727. doi: 10.1038/s41597-022-01830-4.ABSTRACTSeroprevalence studies provide useful information about the proportion of the population either vaccinated against SARS-CoV-2, previously infected with the virus, or both. Numerous studies have been conducted in the United States, but differ substantially by dates of enrollment, target population, geographic location, age distribution, and assays used. This can make it challenging to identify and synthesize available seroprevalence data by geographic region or to compare infection-induced versus combined infection- and vaccination-induced seroprevalenc...
Source: Cancer Control - November 26, 2022 Category: Cancer & Oncology Authors: Neal D Freedman Liliana Brown Lori M Newman Jefferson M Jones Tina J Benoit Francisco Averhoff Xiangning Bu Konuralp Bayrak Anna Lu Brent Coffey Latifa Jackson Stephen J Chanock Anthony R Kerlavage Source Type: research
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial
Lancet Oncol. 2022 Jun 13:S1470-2045(22)00291-1. doi: 10.1016/S1470-2045(22)00291-1. Online ahead of print.ABSTRACTBACKGROUND: In women vaccinated against human papillomavirus (HPV), reductions in cervical disease and related procedures results in more women having intact transformation zones, potentially increasing the risk of cervical lesions caused by non-vaccine-preventable HPV types, a phenomenon termed clinical unmasking. We aimed to evaluate HPV vaccine efficacy against cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and cervical intraepithelial neoplasia grade 3 or worse (CIN3+) attributed to non-preven...
Source: Cancer Control - June 16, 2022 Category: Cancer & Oncology Authors: Jaimie Z Shing Shangying Hu Rolando Herrero Allan Hildesheim Carolina Porras Joshua N Sampson John Schussler John T Schiller Douglas R Lowy M ónica S Sierra Loretto Carvajal Aim ée R Kreimer Costa Rica HPV Vaccine Trial Group Source Type: research
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Defining the risk of SARS-CoV-2 variants on immune protection
We report the development of reagents, methodologies, models, and pivotal findings facilitated by this collaborative approach and identify future challenges. This program serves as a template for the response against rapidly evolving pandemic pathogens by monitoring viral evolution in the human population to identify variants that could erode the effectiveness of countermeasures.PMID:35361968 | DOI:10.1038/s41586-022-04690-5
Source: Cancer Control - April 1, 2022 Category: Cancer & Oncology Authors: Marciela M DeGrace Elodie Ghedin Matthew B Frieman Florian Krammer Alba Grifoni Arghavan Alisoltani Galit Alter Rama R Amara Ralph S Baric Dan H Barouch Jesse D Bloom Louis-Marie Bloyet Gaston Bonenfant Adrianus C M Boon Eli A Boritz Debbie L Bratt Traci Source Type: research
Weekly Overseas Health IT Links – 26th March, 2022.
Here are a few I came across last week.Note: Each link is followed by a title and few paragraphs. For the full article click on the link above title of the article. Note also that full access to some links may require site registration or subscription payment.-----https://mhealthintelligence.com/news/55-of-telehealth-providers-frustrated-with-overblown-patient-expectations55% of Telehealth Providers Frustrated With Overblown Patient ExpectationsProviders also cited their ability to provide quality care and technical difficulties as among their top frustrations with telehealth, a new survey shows.ByAnuja VaidyaMarch 18, 202...
Source: Australian Health Information Technology - March 26, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
What to Know About a Fourth COVID-19 Vaccine Dose
Most people ages 12 and older are considered “up to date” with their COVID-19 vaccines if they received either three doses of the mRNA shots from Pfizer-BioNTech or Moderna, or two doses of Johnson & Johnson’s Janssen vaccine. But some public health experts say another dose might be needed in the coming months.
The Washington Post reports today that Pfizer and BioNTech soon plan to request authorization from the U.S. Food and Drug Administration (FDA) for a fourth dose of their vaccine in people ages 65 and older. In the past few days, Albert Bourla, Pfizer’s CEO, has said that he believes every...
Source: TIME: Health - March 15, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States
Rapid test to support the American public ’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwideThe COVID-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron.EUA granted through Roche ’s participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program to bring rapid tests to the OTC marketBasel, 24 ...
Source: Roche Media News - December 24, 2021 Category: Pharmaceuticals Source Type: news
Global estimates of paediatric tuberculosis incidence in 2013-19: a mathematical modelling analysis
Lancet Glob Health. 2021 Dec 8:S2214-109X(21)00462-9. doi: 10.1016/S2214-109X(21)00462-9. Online ahead of print.ABSTRACTBACKGROUND: Many children who develop tuberculosis are thought to be missed by diagnostic and reporting systems. We aimed to estimate paediatric tuberculosis incidence and underreporting between 2013 and 2019 in countries representing more than 99% of the global tuberculosis burden.METHODS: We developed a mathematical model of paediatric tuberculosis natural history, accounting for key mechanisms and risk factors for infectious exposure (HIV, malnutrition, and BCG non-vaccination), the probability of infe...
Source: Cancer Control - December 13, 2021 Category: Cancer & Oncology Authors: Sita Yerramsetti Ted Cohen Rifat Atun Nicolas A Menzies Source Type: research
NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Spring 2021 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NICDR News
Science Advances
Grantee News
NIDCR News
NIDCR & NIH Stand Against Structural Racism
NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH initiative—called UNIT...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news
Recent Advances on Therapeutic Peptides for Breast Cancer Treatment.
Abstract
Breast cancer is a heterogeneous malignancy which is the second cause of mortality among women in the world. Increasing the resistance to anti-cancer drugs in breast cancer cells persuades researchers to search the novel therapies approaches for the treatment of the malignancy. Among the novel methods, therapeutic peptides which target and disrupt tumor cells have been of great interest. Therapeutic peptides are short amino acids monomer chains with high specificity to bind and modulate a protein interaction of interest. Several advantages of peptides such as specific binding on tumor cells surface, low m...
Source: Current Protein and Peptide Science - November 17, 2020 Category: Biochemistry Authors: Beheshtirouy S, Mirzaei F, Eyvazi S, Tarhriz V Tags: Curr Protein Pept Sci Source Type: research
How Convalescent Plasma Could Help Fight COVID-19
The last time most of us gave any thought to antibodies was probably in high school biology, but we’re getting a crash refresher course thanks to COVID-19. They are, after all, the key to our best defenses against SARS-CoV-2, the virus that’s caused the global pandemic. People who have been infected likely rely on antibodies to recover, and antibodies are what vaccines are designed to produce.
Or at least that’s what infectious-disease and public-health experts assume for now. Because SARS-CoV-2 is such a new virus, even the world’s best authorities aren’t yet sure what it will take to build p...
Source: TIME: Health - August 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Fight Aging! Newsletter, August 24th 2020
We report that electrical stimulation (ES) stimulation of post-stroke aged rats led to an improved functional recovery of spatial long-term memory (T-maze), but not on the rotating pole or the inclined plane, both tests requiring complex sensorimotor skills. Surprisingly, ES had a detrimental effect on the asymmetric sensorimotor deficit.
Histologically, there was a robust increase in the number of doublecortin-positive cells in the dentate gyrus and SVZ of the infarcted hemisphere and the presence of a considerable number of neurons expressing tubulin beta III in the infarcted area. Among the genes that were unique...
Source: Fight Aging! - August 23, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
COVID-19 Pandemic Delays Mesothelioma Clinical Trials
Medical centers across the country have slowed or stopped the enrollment of new patients in mesothelioma clinical trials because of the all-consuming COVID-19 pandemic.
The pause in enrollment options could be critical for newly diagnosed patients with pleural mesothelioma, whose life expectancy is often just six to 12 months.
Clinical trials are research studies where patients can find cutting-edge treatments not yet approved by the U.S. Food and Drug Administration.
Those experimental treatments go beyond standard of care, which generally has not been effective for this rare and aggressive cancer caused by asbestos expos...
Source: Asbestos and Mesothelioma News - April 9, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news
UCLA scientists show how to amplify or stifle signals for immune responses
T cells, the managers of our immune systems, spend their days shaking hands with another type of cell that presents small pieces of protein from pathogens or cancerous cells to the T cell. But each T cell is programmed to recognize just a few protein pieces, known as antigens, meaning years can go by without the T cell, or its descendants, recognizing an antigen.When the T cell does recognize an antigen, it gives the cell presenting the antigen a “hug,” so to speak, instead of a handshake. This initial interaction causes the T cell to search nearby to find other cells that are presenting the same antigen to give them ...
Source: UCLA Newsroom: Health Sciences - March 7, 2017 Category: Universities & Medical Training Source Type: news
